Latest Regulatory Strategy News

Healthcare stocks split into two stories this week: big names sold off hard, while a few small caps ran on clear news. The biggest moves came from a sharp fall in Pro Medicus and Cochlear, while Noxopharm jumped after a top-tier journal publication.

Patrys Limited has appointed Dr Samantha South as its new CEO, aiming to leverage her biotech expertise to fast-track clinical development and commercialisation of its therapeutic antibody pipeline.

Paradigm Biopharmaceuticals has entered a binding agreement with AVet Health to co-develop and license a novel oral therapy for veterinary osteoarthritis in Australia and New Zealand, unlocking new market potential while advancing its human clinical trials.

Memphasys Limited has secured Therapeutic Goods Administration approval for its Felix™ System two months ahead of schedule, enabling immediate commercial sales and clinical use in Australia.

Argenica Therapeutics has won a crucial regulatory waiver from the European Medicines Agency, removing the need for paediatric trials for its stroke drug ARG-007 and clearing the way for faster adult market approval in Europe.

Alterity Therapeutics has bolstered its Phase 2 data for ATH434 in Multiple System Atrophy and is advancing regulatory plans for a pivotal Phase 3 trial, supported by a robust cash position of A$49.2 million.

Artrya Limited has converted three US foundation partners into commercial customers, generating its first fee-per-scan revenues, while progressing FDA clearance for its Salix Coronary Flow module and expanding its clinical study network.

InhaleRx Limited has progressed its clinical trials for three drug candidates targeting cancer pain, panic disorder, and treatment-resistant depression, while securing additional funding and preparing for a company rebrand.

EMC Gold has withdrawn its Salave Gold Project’s strategic interest application to strengthen future submissions, while raising €2.64 million from Spanish investors to advance engineering work.

Clever Culture Systems has expanded its APAS Independence installed base to 27 instruments globally and surpassed $1 million in annual recurring revenue, underpinned by strong sales momentum and customer validation.

BlinkLab Limited has secured independent scientific validation for its smartphone-based autism diagnostic technology through publication in the prestigious journal Autism Research, marking a significant milestone ahead of its FDA regulatory trial.

Dimerix has successfully completed recruitment and dosing of 286 adult patients in its Phase 3 ACTION3 trial evaluating DMX-200 for focal segmental glomerulosclerosis (FSGS), advancing toward regulatory discussions with the FDA.